We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tryptophan and Behavior Therapy for Cocaine Abuse - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000324
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : January 12, 2017
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to assess the efficacy of tryptophan vs. placebo, and voucher payments vs. a control condition, in the treatment of cocaine dependence.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Drug: Tryptophan Phase 2

Detailed Description:
This clinical trial uses a 2 by 2 design to compare tryptophan to placebo, and voucher incentives vs. a control condition, in the outpatient treatment of cocaine dependence- using a relapse prevention model of treatment intervention.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Official Title: Tryptophan and Behavior Therapy for Cocaine Abuse
Study Start Date : March 1997
Estimated Study Completion Date : April 2001

Resource links provided by the National Library of Medicine

Drug Information available for: Tryptophan
U.S. FDA Resources




Primary Outcome Measures :
  1. Side effects
  2. Retention
  3. Cocaine use
  4. Cocaine craving
  5. Other drug use
  6. Psychosocial functioning


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cocaine dependent

Exclusion Criteria:

  • Physically dependent on drugs of abuse other than cocaine
  • Significant medical or psychiatric illness (besides substance abuse disorder)
  • Pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000324


Locations
United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Johns Hopkins University
Investigators
Principal Investigator: Eric C Strain, M.D. Johns Hopkins University

Publications:
Jones H.E., Johnson, R.E., Bigelow G.E., Strain E.C. Differences at treatment entry between opioid-dependent and cocaine-dependent males and females. Addictive Disorders and Their Treatment 3:110-121, 2004.

ClinicalTrials.gov Identifier: NCT00000324     History of Changes
Other Study ID Numbers: NIDA-10754-1
R01-10754-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: August 2005

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Tryptophan
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs